Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio

Benzinga_recent_news04-10

Anbio Biotechnology (NASDAQ:NNNN) reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in 2024. Net income surged to $6.4 million, up from $2.37 million, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626131438?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/09/Close-up-View-To-Micromanipulation-With-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-10 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626131438","market":"us","top_or_hot":-1,"title":"Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio","media":"Benzinga_recent_news","content":"<div>\n<p>Anbio Biotechnology (NASDAQ:NNNN) reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in 2024. \nNet income surged to $6.4 million, up from $2.37 million, ...</p>\n\n<a href=\"https://www.benzinga.com/markets/earnings/26/04/51737825/anbio-biotechnology-posts-solid-fy25-results-diversifies-portfolio\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-10 00:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/earnings/26/04/51737825/anbio-biotechnology-posts-solid-fy25-results-diversifies-portfolio><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Anbio Biotechnology (NASDAQ:NNNN) reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in 2024. \nNet income surged to $6.4 million, up from $2.37 million, ...</p>\n\n<a href=\"https://www.benzinga.com/markets/earnings/26/04/51737825/anbio-biotechnology-posts-solid-fy25-results-diversifies-portfolio\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/markets/earnings/26/04/51737825/anbio-biotechnology-posts-solid-fy25-results-diversifies-portfolio","article_id":"2626131438","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/09/Close-up-View-To-Micromanipulation-With-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/earnings/26/04/51737825/anbio-biotechnology-posts-solid-fy25-results-diversifies-portfolio","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626131438","pubTimestamp":1775753160,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Anbio Biotechnology reported strong 2025 results with sales of $8.65M. The company is diversifying away from COVID products.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","POCT":"Innovator U.S. Equity Power Buffer ETF - October","NNNN":"Anbio Biotechnology"},"translate_title":"Anbio Biotechnology公布稳健的2025财年业绩，实现投资组合多元化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POCT":1,"NNNN":1.5},"content_text":"Anbio Biotechnology (NASDAQ:NNNN) reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in 2024. \nNet income surged to $6.4 million, up from $2.37 million, while earnings from continuing operations jumped to 15 cents per share from 6 cents.\nGross margin expanded to 87.2% from 71.9%, driven by a higher-margin product mix and an outsourcing-led model, boosting profitability. Return on equity improved to roughly 21.1%.\nAnbio, a medical technology and vitro diagnostics (IVD) company, has been actively diversifying away from COVID-19 diagnostics. In 2025, the company launched:\nAnbio Biotechnology generated 80.4% of its commercial IVD revenue from non-COVID products in 2025. \"Our strategy in 2025 was to build a more diversified and sustainable diagnostics business,\" said Michael Lau, CEO of Anbio Biotechnology. \"By expanding into non-COVID IVD products, veterinary diagnostics and new testing platforms, we believe we are positioning the company for long-term growth and stronger profitability.\"\nAnbio Biotechnology is transitioning to a broad multi-disease testing portfolio, including:\nWith its Point-of-Care Testing (POCT) products, Anbio Biotechnology addresses a large and growth IVD market.\nThe global IVD market is projected to grow from an estimated $109.06 billion in 2025 to $157.63 billion in 2030. That represents a CAGR (compounded annual growth rate) of 7.6%.\nNNNN Price Action: Shares of Anbio Biotechnology have risen by 21.30% to $26.94 over the past month.\nImage: Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626131438","isCrawlerRequest":true}